Work

Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.

Year: 2010
Type: article
Abstract: The Evolving Picture of IBD The past ten years have witnessed tremendous advances in our understanding of inflammatory bowel disease (IBD) etiopathogenesis and our ability to treat patients suffering from its two major forms, Crohn's disease (CD) and ulcerative colitis (UC). In prior decades, IBD patients endured a lack of effective treatment options, and patients with moderate-to-severe CD and UC were often relegated to prolonged systemic corticosteroid therapy and surgery as their only options. From the late 1990s onward, there has been a significant change in IBD therapy, specifically the widespread adoption of maintenance immunomodulators and the advent of biologic agents. Although highly effective, these new therapeutic approaches have been accompanied by important questions regarding medication safety, specifically in the setting of long-term maintenance treatment. Additional questions have emerged about how to best use these agents, along with a pressing need to define optimal treatment algorithms for specific IBD subgroups (ie, patients with pan-enteric inflammation, patients requiring hospitalization, patients with rapid recurrence of disease following resection/reanastomosis). Understanding the natural history of these at-risk IBD patient subgroups, particularly early identification of patients with the potential for severe disease and its associated complications, will ultimately determine an optimal clinical approach that incorporates appropriate risk-benefit assessment for disease modifying therapy.
Author: David G Binion
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W85544848
FWCI: 0.531
Cites: 33
Cited by: 17
Related to: 10